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Amphibian skin secretions are rich resources of bioactive peptides, some of which 
could be developed as drug candidates. Among these natural peptides, antimicrobial 
peptides have attracted great attention given that they might help to deal with the prob-
lem of antibiotic resistance.  
In this study, the precursor-encoding cDNA sequence of a novel bioactive peptide 
QUB-2552 was identified in the skin secretion of Chinese Large Odorous frog, Rana 
(Odorrana) livida, by applying ‘Shotgun’ cloning method. The novel peptide was syn-
thesised by using Solid Phase Peptide Synthesis strategy. After the synthetic peptide 
was identified and purified by Matrix-assisted, laser desorption, ionisation, time-of-
flight (MALDI-TOF) and Reversed-Phase High Performance Liquid Chromatography 
(RP-HPLC). QUB-2552 was subjected to functional tests and it was found to have 
moderate antimicrobial effect against C. albicans and S. aureus. Meanwhile, it has 
weak inhibitory effect against PC-3 and U251MG, but it did not exhibit haemolytic 
effect. 
 
It is expected that this study will contribute to the finding of novel AMPs and the de-
























































1. A brief introduction to amphibians and Chinese Large Odorous frog, Rana 
(Odorrana) livida. 
1.1 Brief review of amphibians 
Amphibians are ectothermic, tetrapod vertebrates that belong to Class Amphibia. The 
earliest amphibians came from the sarcopterygian fish of the Devonian Period, and 
these fish had lungs and bony-limbed fins.. 
 
Amphibians live in a variety of habitats, such as terrestrial, arboreal, fossorial or fresh-
water aquatic ecosystems. Typically, amphibians live in water as larvae. However, 
some species which have developed behavioural adaptions can bypass this larvae stage. 
The life stages of amphibians are as follows: firstly, amphibians lay eggs in water and 
the larvae live in the aquatic environment. After birth, most amphibians go through a 
process called metamorphosis, which results in a significant morphological change. 
During this process, amphibians turn form larvae with gills to an adult with lungs 
(Newman, 1992).  
 
In addition to lungs, the skin of amphibians, which is water-permeable, also served as 
a breathing organ. This enables adult amphibians to respire and hibernate in water 
(Arnold, 2002). As compensation for the amphibian’s thin and delicate skin, mucous 
glands have been developed which can produce secretions to keep the skin moist. Apart 
from that, mucous secretion is also regarded as the first defence line in the amphibian, 
because the secretion is sticky and distasteful which makes it difficult for their preda-
tors to capture them. Furthermore, most amphibians have granular glands which can 




 1.2 Chinese Large Odorous frog, Rana (Odorrana) livida. 
Odorrana livida is a genus of Ranidae (true frog) originate from East Asia and neigh-
bouring regions. Where they mostly live in fast-flowing mountain streams. They have 
acquired a common name, tip-nosed frog, because they have a significant pointed 
snout. 
The systematic history of Odorrana is complicated. Most species were initially cate-
gorized in Rana and then subsequently some reclassified in Odorrana while others 
were classified in Amolops, Huia, and Eburana instead (Bhuiyan et al., 2003). In re-
cent years, molecular phylogenetic has finally found the reason for the systematic con-
fusion of Odorrana; it is because that the evolution between Huia, Amoiops, and Odor-
rana, which are significant lineages of Raninae, is convergent. In addition, Rana may 
be the closest relative and living lineage of Odorrana. Although there is no definitive 
evidence for Odorrana being a distinct genus, the existing evidence heavily suggests 
it (Stuart, 2008). 
Odorrana livida is a species of frog belonging to Ranidae family. They are distributed 
in China as well as in other countries such as Thailand in Southeast Asia. In China, 
they spread across many provinces such as Yunnan province, Guizhou province, Fujian 
province, etc. Their habitat could either be dense forest or large mountain streams.                
 
2. Amphibian skin secretions 
The skin of amphibians is typically exposed to parasites, microorganisms, predators 
and physical factors. Amphibians are typical animals that the evolutionary water-land 




Mucous glands and granular glands are the main glands in the amphibian skin, and 
they are the source of most secretions in amphibian skin. In amphibians, mucus glands 
can help to keep skin moist thereby protect the skin from harmful effects. The granular 
glands secret a broad range of agents, which protect amphibian against microbial in-
fection and their predators (Daly, 1995). These agents range from being slightly nox-
ious to extremely toxic. Research of amphibian skin secretion has been undertaken for 
several reasons; they are a valuable source for biophysical study, for biochemical tax-
onomy and for searching for new pharmaceuticals. Amphibians have been used in 
medicine in many ancient cultures. For example, in traditional Chinese medicine, frog 
and toad skin is named Chan Su and has been used as a kind of the traditional Chinese 
medicine. It has been used to treat a variety of conditions, such as heart disease, tooth-
ache, sinusitis and haemorrhage of gums (Bhuiyan et al., 2003). 
In summary, amphibian skin secretions are regarded as a “treasure house” with much 
potential for further development of novel medicines. 
 
2.1 Bioactive compounds in amphibian skin secretions 
The chemical compounds in amphibian skin secretions are complicated, and there are 
four categories of the secretions in granular and poison glands; biogenic amines, bufa-
dienolides (bufogenins), alkaloids and steroids, peptides and proteins (Clarke, 1997). 
2.1.1 Biogenic Amines 
Biogenic amines come from various sources such as vegetables, animals, and micro-
bial metabolisms. Generally, biogenic amines have two different kinds: the one is 
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amino acid decarboxylation, and the other is amination and transamination of alde-
hydes and ketones. Derivatives of indolealkylamines and catecholamines are classified 
into biogenic amines. Based on origins and chemical features, aromatic amines can be 
categorised into three groups: indolealkylamines, phenylalkylamines, and imidia-
zolealkylamines (Clarke, 1997). The indolealkylamines contain 5-hydroxytryptamine 
and the derivatives of N-methylate. The 5-hydroxytryptamine presents in major am-
phibian genera, and the other one exists in a range of salamander, toads, and frogs 
(Bennett et al., 1981). However, the imidiazolealkylamines and related histamine are 
only from leptodactylid and hylid frogs. The hydroxy phenylalkylamines are from lep-
todactylid frogs, and epinephrine are found in Bufo sppCei. Erspamer & Roseghini 
(Cei et al., 1968) and Cei et al have screened 65 species and subspecies of Bufo. They 
concluded that different species and subspecies own their specific biogenic amines in 
the skin. Therefore, biogenic amines can be used to characterise evolutionary lineages. 
2.1.2 Bufadienolides and steroids 
Bufotenine is chemically classified to steroid group of compounds, and the molecular 
formula is C24H34O2.  Cardenolide glycosides and bufadienolide glycosides are the 
most common types of bufadienolides (Ye et al., 2004). Ventricular tachycardia, lethal 
cardiac and bradycardia act as an atrioventricular block and they can be caused by 
bufadienolides and their glycosides, and both of them are acknowledged to be toxic. 
 
2.1.3 Alkaloids 
Alkaloids belong to cyclic nitrogen, and their distribution in nature is restricted. They 
were at one time thought to be only produced by the plant kingdom, but afterwards, 
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alkaloids were found in various animals, and amphibians are proved to be the main 
source of alkaloids (Clarke, 1997). Among amphibians, alkaloids are mainly found in 
poison dart frogs (family Dendrobatedae) and they also present in salamanders (S. 
Salamandra), newts (Triturus spp. And Taricha spp.) and some genera of toads and 
frogs, such as harlequin frogs Atelopys spp., the mantelline ranid frogs, Mantella spp., 
the myobatrachid frog Pseudophryne corroboree, and the cane toad Bufo marinus (Daly 
et al., 1987). 
2.1.4 Peptides and proteins 
Peptides are important bioactive compounds in skin secretions of amphibians. They 
are held in granular glands and can be produced in high concentrations into skin secre-
tions when the amphibian is injured or stressed. Peptides can be classified into hun-
dreds of peptide families including Magainin family, Cecropin family, Cathelicidin 
family, Defensin family, opioid peptides, pheromone peptides and other peptide fami-
lies (Clarke, 1997, Zasloff, 1987). Numerous discoveries of new bioactive peptides 
and proteins in amphibian gland secretions has encouraged a wide range of researches 
to study the amphibian bioactive compounds in secretions (Csordas and Michl, 1969, 
Croce et al., 1973, Barberio et al., 1987). In the past few years, the most significant 
discovery in this research area may be the magainins, which was extracted from the 
skin secretions of the African clawed toad (Magainins, 1987). Magainins show a wide 
range of antimicrobial activities. It is capable of inhibiting the growth of both Gram-
negative and Gram-positive bacteria (Zasloff, 1987). This discovery has encouraged 
massive amount of research to study peptides and proteins derived from amphibians 
(Bevins and Zasloff, 1990, Zasloff, 1987). 
As more and more researchers study amphibian skin peptides, the bioactivity of the 
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peptide has become more significant. Bevins & Zasloff found that frog skin secretion 
is a “treasure house” of peptides with significant antimicrobial activity. In particular, 
amphibian skin peptides are also promising candidates for treating HIV, cancer, and 
drug-resistant S.aurers, which are the main challenges facing the 21st-century medical 
community (Xu and Lai, 2015). 
2.2 Toxicity of amphibian skin secretions 
Among vertebrates, amphibians are remarkable for various noxious compounds that 
are stored in granular skin glands. These agents include peptides, amines, steroids, and 
both lipid-soluble and water-soluble alkaloids (Daly, 1995). The parotoids are the main 
glands to produce poison, and they are commonly existed on the back of frogs, on the 
upper surface of caecilians, behind the eyes of salamanders and the ears of toads, and 
they are the area that usually exposed to predators. The toxins in skin secretion usually 
taste foul and can cause physical or neurological detriment (Rodríguez et al., 2017).  
Secretion toxins are the main self-defence method for amphibians against predators, 
the high level of vasoactive peptides such as bombesin, diamorphine, bradykinin, etc., 
apparently, serve in defence against predators. Up to now, only a restricted number of 
amphibian species have been researched, from which more than 200 poisons have been 
discovered (Xu and Lai, 2015).  
2.3 Pharmaceutical significance of amphibian skin secretions 
Nowadays, although antibiotics can be effective against bacterial and fungal infections, 
the resistance to some antibiotics and toxicity of currently available antibiotics has 
become a big problem. As a lot of peptides derived from amphibian skin secretion has 
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been found to have antimicrobial functions (Galdiero et al., 2015). Therefore, it is pos-
sible that compounds extracted from amphibian skin secretion are promising substi-
tutes or additional treatments, especially as antimicrobial agents. 
In addition, the amphibian skin has respiratory and antimicrobial functions; thus it is 
possible that compounds derived from amphibian skin secretion can become potential 
candidates for treating respiratory and skin infections (Clarke, 1997).  
Furthermore, another exciting discovery is that some frog (Breviceps spp.) can synthe-
sise a natural ‘glue' to bind with their mate during reproduction. Although more re-
searches are needed to explore how frogs separate from each other, it is likely to use 
these bio-adhesives as biocompatible glues which have promising application in plas-
tic surgery as well as wound-healing (Abbott, 1990). 
 
3. Antimicrobial peptides (AMPs) 
The development of antimicrobial resistance to traditional antibiotics has become a 
major global health problem, and antimicrobial peptides have emerged as a significant 
substitute for conventional antibiotics because of their broad-spectrum activity that can 
act against different microorganisms (Galdiero et al., 2015). Antimicrobial peptides 
are also used as a kind of basic agent of innate immunity. Recent research has proven 
their effectiveness against a wide range of conditions, such as allergies, cancer and 
susceptibility to infection, including HIV/AIDS (Zhang and Carmichael, 2016). 
Normally, AMPs are short polypeptides and their lengths in sequences are at most 60 
amino acids, and commonly the lengths are between 15 and 40 residues. Almost all 
AMPs have a positively charged surface. Although AMPs are commonly unstructured 
in aqueous solution, a membrane mimetic environment leads AMPs to form a structure 
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and induces considerable amphipathicity, which means that hydrophilic residues lie on 
one side of the peptide and hydrophobic residues and hydrophobic residues lie on the 
other side (Galdiero et al., 2015). 
 
3.1 Function of AMPs 
Antimicrobial peptides are highly effective in that they are able to kill a wide range of 
microorganisms such as gram-negative and gram-positive bacteria, fungi, parasites 
and viruses with different mechanisms of action. According to the antimicrobial activ-
ities of AMPs, they can be grouped into different classes (Li et al., 2014). 
3.1.1 Anti-bacterial activity 
Anti-bacterial activity is the most significant function of AMPs. They can kill bacteria 
quickly and their mechanisms of killing bacteria are different from that of traditional 
antibiotic, which makes it less likely to lead to antimicrobial resistance development. 
Thus, AMPs are excellent candidates for clinical exploitation (Clarke, 1997). 
 
3.1.1.1 Anti-Gram-positive bacterial activity 
In the Gram staining test, the colour of Gram-positive bacteria is purple when it is 
observed under a microscope. And in the bacterial differentiation method, Gram-pos-
itive bacteria demonstrates a positive result; because their peptidoglycan layer is thick. 
In addition to the feature of thick peptidoglycan layer, Gram-positive bacteria also has 
two other unique features: cytoplasmic lipid membrane and cross-linked peptidogly-
can chains. Apart from that, they also have teichoic acids and lipoids (Madigan and 
Martinko, 2006).  
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Commonly, pathogenic Gram-positive bacteria are classified into six genera in humans; 
two kinds of them are cocci and the other kinds are bacilli. The two cocci genera are 
Streptococcus and Staphylococcus. Some genera can form spores, and some genera are 
not capable of forming spores. According to this feature, they are classified into two 
sub-groups: Bacillus and Clostridium which can form spores and Corynebacterium 
and Listeria which cannot. All these three genera, Rathybacter, Leifsonia, and Clavi-
bacter, can cause plant diseases (Imamura et al., 2009). 
Antibiotics are effective against Gram-positive bacteria due to the absence of outer 
membranes in them. However, because of the increasing problem of antibiotic re-
sistance, a novel treatment is highly needed to solve this problem and cure infections 
which were caused by antibiotic-resistant microorganisms. AMP5 Isoform 5, which 
was discovered in immunised insect larvae, was acknowledged to have high effective-
ness for killing Gram-positive bacteria, Micrococcus luteus (Imamura et al., 2009). 
Generally, AMPs which only have the anti-Gram-positive ability are fewer than mul-
tifunctional AMPs. 
 
3.1.1.2 Anti-Gram-negative bacterial activity 
In the Gram stain test, the colour of Gram-negative bacteria is red when it is observed 
under a microscope. Gram-positive bacteria and Gram-negative bacteria are universal 
and Gram-negative bacteria are more common than Gram-negative bacteria. An ap-
parent difference between Gram-negative bacteria and Gram-positive bacteria is that 
the peptidoglycan layer in Gram-negative is thinner than that in Gram-positive bacteria. 
In Gram-negative bacteria, the peptidoglycan layer is placed between a bacterial outer 
membrane and an inner cell membrane (Madigan and Martinko, 2006).  
Many studies of Gram-positive bacteria have shown that Gram-positive bacteria could 
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be the main reactors to antibiotics. While Gram-negative bacteria is usually resistance 
to antibiotics. One significant difference between Gram-negative and Gram-positive 
bacteria is that Gram-negative bacteria has outer cell membrane while Gram-positive 
bacteria do not. The outer cell membrane withstand antibiotic selection pressure which 
possibly is the main reason for resistance to antibiotics (Gupta, 2011). However, the 
reason why a large number of studies are interested in the anti-Gram-negative bacterial 
function in AMPs is that the anti-Gram-negative mechanism of AMPs is remarkably 
different from that of other antibiotics. For example, Hiinavin is a peptide, and it was 
extracted from the larval haemolymph of the cabbage butterfly. When it was tested on 
antimicrobial activities, it showed remarkable antimicrobial effectiveness against the 
Gram-negative bacteria and Gram-positive bacteria. And the effect against Gram-neg-
ative bacteria was stronger than Gram-positive bacteria. In addition, it also exhibited 
a significant synergism with lysozyme (Yoe et al., 2006). 
Generally, the most common AMPs are those with both anti-Gram-negative and anti-
Gram-positive bacterial functions. One particular example is the peptide with a se-
quence – NPSRQERR, and it can react powerfully against Gram-positive bacteria such 
as Staphylococcus aureus and Gram-negative bacteria like Escherichia coli EAEC 042 
and Salmonella typhi (Lu et al., 2009). Another peptide, extracted from Nasonia vit-
ripennis, could act effectively against Gram-positive bacteria, Gram-negative bacteria 
and fungi (Ye et al., 2010). 
3.1.1.3 Anti-fungal activity 
Up to now, more than 70000 species of fungi have been known, and some of them are 
used for food production and some can be used in therapies. As more and more fungi 
become resistant to antibiotics and most present medicine has restricted target speci-
ficity, some anti-fungal peptides come to be a new alternative treatment for medical 
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use. For example, three peptides named OdVP1, OdVP2 and OdVP3 were derived 
from Orancistrocerus drewseni. They showed significant effectiveness against fungi. 
Subsequently, after some modifications, the OdVP2L exhibited extraordinary effec-
tiveness against Botrytis cinerea. But the modified OdVP2 did not possess any efficacy 
against bacteria (Baek and Lee, 2010). 
3.1.2 Anti-viral activity 
Viruses can cause many diseases, they are able to infect all kinds of living organisms. 
They are also capable of replicating themselves in host cells. So far, antibiotics are 
effective against viruses, and although anti-viral medicines can prevent viruses from 
replicating, they do not have the capability to kill viruses. Currently, anti-lipopolysac-
charide peptides (SALPs) have been discovered. They are a novel group of peptides 
and they have a wide spectrum against viruses. The mechanism of anti-viruses of 
SALPs is that they can obstruct the way that flu viruses infect host cells (Hoffmann et 
al., 2014). Thus, SALPs offer the potential for the discovery of a new substitute to cure 
flu virus infections. Furthermore, the peptide, P3, displayed a vital function against 
Japanese encephalitis virus (JEV). JEV is able to cause an acute disease. P3 can bind 
on its specific receptor in the binding region, which is the mechanism to hinder the 
viral replication (Zu et al., 2014). 
3.1.3 Anti-cancer activity 
Cancer is the main cause of death in recent years; it does great harm to human health. 
Chemotherapy, radiotherapy and surgery are three conventional therapies for cancer 
treatment but all of these three treatments are not extremely specific. Besides, they 
could result in unavoidable side effects to normal human cells (Amit and Hochberg, 
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2012). It is easy to develop Multi-drug resistance (MDR) of cancers from typical anti-
cancer drugs. Many studies have been carried out in the past few years, it has been 
shown that both natural and synthetic AMPs have cytotoxic function against a broad 
range of cancer cells and can be a promising new therapy for cancer (Bhutia and Maiti, 
2008).  
3.2 Classification of AMPs 
So far, according to different standards, there are various methods to categorise AMPs. 
Based on the primary structures of AMPs, AMPs can be classified into several peptide 
families. When it comes to the secondary structures, it includes α-helices, β-sheet, β-
turns and random coils. Generally, AMPs have more than two kinds of structures, 
which is the reason why their structures are complex. According to the differences and 
similarities of their structures, AMPs can be categorised into three main categories: α-
helical, β-sheet and extended peptides. In nature, the most common and classic kinds 
of AMPs are α-helical peptides and β-sheet peptides. A great number of synthetic pep-
tides can be categorised into the above-mentioned three main classes (Ong et al., 2014). 
3.2.1 α-helical AMPs 
As for α-helical AMPs, the hydrophobic group is applied to measure amphipathic fea-
tures (Figure 1.1). In this structure, AMPs have hydrophobic groups and hydrophilic 
groups, and both of them can interact with phospholipid membranes. Because of their 
amphipathic characteristics, they are located opposite to each other on the surface. As 
for antimicrobial activity of AMPs, when the hydrophobic group of AMPs is rising 
within proper ratios of hydrophobicity to charged groups, it can lead to increased an-
timicrobial activities. But as the hydrophobic level goes up, it will cause increment 
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cytotoxicity in eukaryotic and lose antimicrobial properties. Among these three classes 
of AMPs, most studies are focused on α-helical peptides, and as a result of numerous 
studies, most AMPs which can destroy cell membrane including α-helical structure. 
However, not all peptides with α-helical structure are able to interact with cell mem-
branes (Yeaman and Yount, 2003). 
 
Figure 1.1 α-helix secondary structure of AMPs (Ong et al., 2014). 
 
3.2.2 β-sheet AMPs 
Commonly, the standard for β-sheet AMPs is whether they use disulfide bonds as sta-
bilisers to set up antiparallel β-sheet or not (Figure 1.2). The β-hairpin peptides also 
belong to β-sheet AMPs. The most typical peptide of this class is the tachyplesins. 
They were discovered in the Japanese horseshoe crab, Tachyplesus tridentatus, and it 
is made up of 17 to 18 amino acids. Considering that the NMR structures of the rea-
sonable length tachyplesins are well set up, abundant studies have been carried out to 
disclose the relationship between β-sheet structures and biological activities. One AMP, 
tachyplesin I, includes an antiparallel β-sheet structure and the relationship between 
the structure and antimicrobial function in vitro has been studied. However, the mech-
anism of the relationship between the structure and function of AMPs has not been 





Figure 1.2 β-sheet secondary structure of AMPs (Ong et al., 2014). 
 
3.2.3 Extended AMPs 
As for the structure of extended AMPs, it is curved rather than the regular secondary 
structure (Figure 1.3). Numerous extended peptides are not capable of interacting with 
cell membranes. Some extended peptides like apidaecin, drosocin and pyrrhocoricin 
are extracted from insects, and the mechanism of their antimicrobial activities is that 
they can interact with intracellular targets such as the proteins DnaK and GroEL 
(Brogden, 2005). 
 
Figure 1.3 Extended secondary structure of AMPs (Ong et al., 2014). 
 
3.3 Mechanism of AMPs action 
So far, the mechanism of AMPs action has been reviewed in many studies. The most 
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commonly accepted models of AMP bilayer interaction and bacterial membrane per-
meabilization are these three models: barrel-stave models, toroidal pore and the carpet-
like (Lee et al., 2016). Generally, it is proposed that cationic amino acid residues of 
AMPs are attracted on the membrane surface via electrostatic interactions with anionic 
phospholipid groups, which leads to membrane lysis, membrane depolarization, and 
the cell death. 
3.3.1 The “barrel-stave” model 
The first time that the barrel-stave model came out is to explain the single channel 
conductance caused by alamethicin in black lipid membranes (Baumann and Mueller, 
1974). In this model, the AMP attaches to the membrane by electrostatic forces, and to 
adapt to the amphipathic structure of the membrane, it changes into a parallel hydro-
phobic-hydrophilic group with the phospholipid chains. When peptides reach a critical 
threshold of concentration, the individual peptides will self-assemble and become a 
larger structure which is made up of a changeable amount of peptides that insert per-
pendicularly and more deeply into the membrane forming a ring that is similar to a 
"barrel" pore (Figure 1.3). "Stave" relates to the individual spokes within the barrel. 
In the structure of this pore, the hydrophobic domains of the peptide face outside to-
ward the hydrophobic regions of the membrane core and the hydrophilic groups face 
inside toward the aqueous pore. This structure leads to minimise exposure of the hy-
drophilic groups to the hydrophobic tails of the lipids and the hydrophobic domains of 




3.3.2 The “toroidal pore” model 
The mechanism of “toroidal pore” model is similar to the “barrel-stave” mode of pore 
formation. The “toroidal pore” model was firstly proposed from studies of α-helical 
AMPs such as PGLa and magainins (Hara et al., 2001a, Hara et al., 2001b). The pep-
tides bind to the membrane surface and go through similar secondary structural 
changes as the barrel-stave model. The form of helices is primarily orientated parallel 
to the membrane, and the hydrophobic side of the helix binds to the phospholipid head 
groups of the membrane and displaces them. This behaviour leads to a gap in the hy-
drophobic region and causes a positive curvature strain on the membrane. As mem-
brane thinning occurs, this strain can destabilize the integrity of the membrane which 
is able to make the surface of the membrane more vulnerable to AMPs. When peptides 
achieve a critical concentration, they self-assemble and insert perpendicularly to the 
membrane and the hydrophobic groups of peptides are no longer exposed to the lipid 
head groups, and toroidal pore complexes are formed as shown in Figure 1.7. The 
difference between “barrel-stave” model and this model is that the AMPs in this model 
still interact with the lipid head residues and they are not situated in the membrane 
hydrophobic core. The pore in this model is not as stable as that in barrel-stave model, 
and therefore the pore is more short-lived. In addition, the peptide charge can affect 
the stability of the pore. A great number of positive side chains can lead to repulsion 
and produce pores with shorter half-lives. When the pore complex disintegrates, some 
AMPs can translocate to the luminal side of model membranes. It seems that this 
mechanism may also be a way in which peptides can come to potential intracellular 
targets (Kumar et al., 2018).  
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3.3.3 The “carpet-like” model 
In the “carpet-like” mechanism, peptides are parallel to the membrane surface in a 
similar way to the "barrel-stave" model and the "toroidal pore" model described here, 
and the peptides are primarily bound to specific target membranes via electrostatic 
interactions. Once the peptide binds to the membrane, it will undergo a conformational 
change, but it doesn't undergo further quaternary structure formation and the hydro-
phobic groups may or may not insert into targeted membrane core. When a critical 
concentration of peptides is achieved, they will effectively cover the surface of the 
membrane and insert and scatter the membrane "carpet-like," and this makes the mem-
brane more energetic and fluid until the membrane structure is unstable and no longer 
can be maintained (Figure 1.4). At the last step of the "Carpet - Like" mechanism, the 
membrane structure collapse into micelles (Lee et al., 2016).  
 
Figure 1.4 Mechanisms of antimicrobial peptides (AMPs: (a) barrel-stave model, (b) carpet or detergent 




3.4 Clinical significance of AMPs 
So far, more and more bacteria come to exhibit resistance to the traditional antibiotics, 
which becomes a global challenge in the 21st century.  And AMPs can be an attractive 
substitute as new medical antibiotic. It is because that the antimicrobial mechanisms 
of AMPs are different from traditional antibiotics and AMPs have several different 
antimicrobial mechanisms. For example, some AMPs can destroy the formation of 
bacterial biofilm, thus inhibiting bacterial infections. They also have broad-spectrum 
activities against microorganisms (Seo et al., 2012). Although AMPs do not exhibit 
more advantage than conventional antibiotics targeting susceptible pathogens (Marr et 
al., 2006), AMPs has a different antimicrobial mechanism which may have the potency 
to destroy multi-resistant bacteria. Furthermore, AMPs are capable of killing bacteria 
rapidly, and they have many different cellular acting sites (Brogden, 2005). So, AMPs 
become a promising solution to the bacterial resistance problem. Apart from that, when 
antibiotics and AMPs are used together on antimicrobial tests in vivo, the activity of 
antibiotics can become efficiently (Zasloff, 2002). This explained that may be the 
AMPs can make antibiotics come into target cell more efficient. Therefore, they can 
not only be used as single antimicrobial chemicals but also worked as synergists with 
present antibiotics (Marr et al., 2006). Apart from being immunomodulatory chemistry, 
AMPs can also affect against endotoxin (Yeung et al., 2011). In addition to several 
possible applications, AMPs are less likely to gain antibiotic resistance. It is because 
that most AMPs do not have distinct epitopes in their amino acid sequences. The 
epitopes served as protease recognition sites which lead pathogens to disrupt the func-
tional activity of AMPs on cell membranes (Zasloff, 2002). Besides, the types of AMPs 
are numerous, which makes it impossible for microbes to be resistant to all peptides. 
So far, bacteria have three potential mechanisms to resistant to some AMPs, and they 
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can degrade proteolysis, pump efflux and modify cell surface. But compared to the 
resistance to present antibiotics, the resistance effect to AMPs is much gentler (Marr 
et al., 2006, Yeung et al., 2011). Moreover, AMPs have several different targets con-
taining cell wall biosynthesis and cytoplasmic membrane permeability barriers, which 
makes microbes less likely to resistant to AMPs (Yeung et al., 2011). 
4. Aims of this thesis 
The aims and objectives of this project were as followings: 
1). To use molecular cloning method to identify the cloned cDNA nucleotide sequence 
encoding the novel peptide. 
2). To use the PS4 Tribute peptide synthesiser to synthesise enough peptide for biolog-
ical evaluations. 
3). To evaluate the biological activities of the synthetic peptide, such as antimicrobial 
activity, anti-cancer activity, haemolytic activity. 
4). To gain an overview knowledge about the methods for developing novel medicine 
in early steps. 






















































2.1 Specimen biodata and secretion harvesting 
Specimens of Chinese Large Odorous Frog, Rana (Odorrana) livida, were captured in 
the People’s Republic of China. All frogs were adults and were settled into their re-
spective vivaria in the Institute of Biotechnology, University of Fuzhou. After four 
months, skin secretions were obtained by mild squeezing and massaging of the glands 
with gloved fingers. The harvested secretions were washed from the skin by deionised 
water, snap-frozen in liquid nitrogen and lyophilised. The lyophilised product was 
stored at -20℃ prior to analysis. All animal experiments were conducted according to 
local, institutional, and national guidelines. 
 
2.2 “Shotgun” cloning 
2.2.1 mRNA isolation from Rana (Odorrana) livida skin secretion 
The purpose of mRNA isolation was to extract mRNA from the secretions from the 
frogs. In this section, a Dynabeads® mRNA DIRECT™ Kit (BIOTECH, UK) was used 
to isolate pure poly-A mRNA frog skin secretion. This mechanism relied on A-T base 
pairing. Short sequences of oligo (dT)25 bonded to the surface of magnetic Dynabeads 
by covalent bonds and the poly (A) tails of mRNAs could combine and form Dyna-
bead/mRNA hybrids. With the help of magnetism, mRNAs could be extracted rapidly 
from sample lysates. The hydrogen bond between oligo (dT)25 and mRNA could be 
damaged by high temperature in mRNA elution so that mRNA could be isolated from 




Figure 2.1 poly-A mRNA isolation using Dynabeads. The protocol can be used in all downstream 
applications. 
(https://www.thermofisher.com/uk/en/home/life-science/dna-rna-purification-analysis/napamisc/mrna-
isolation-dynabeads.html, accessed on: 14th November, 2017) 
 
In the experiment, 5 mg of lyophilised Rana (Odorrana) livida skin secretion were 
dissolved in 1 ml of lysis/binding buffer in a tube labelled A. Tube A was vortexed for 
1 min and cooled on ice for 1 min to protect mRNA from enzymolysis. This step was 
performed 5 times. Then the tube was centrifuged at 18,000x g for 5 min in an Eppen-
dorf Centrifuge 5424 (Eppendorf, Germany).  
Dynabeads (5 mg/ml) were suspended in the storage vial and 250 μl of the suspension 
was added to another tube labelled B. Tube B was placed on a magnetic rack, then the 
supernatant was removed by a pipette when the suspension became clear. Afterwards, 
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250μl of lysis/binding buffer was added to tube B after it was taken out of the magnetic 
rack, and the tube was put on the rack again. When the suspension became clear, the 
supernatant was discarded with Dynabeads remaining.  
After centrifugation, the supernatant (sample lysate) in tube A was removed to tube B. 
Tube B was gently shaken and rotated for 1 min then placed on ice for 1 min. This step 
was subsequently repeated 9 times. After this, tube B was placed on the magnetic rack 
again and the supernatant was removed to obtain the beads which were bound with 
mRNAs. 
To wash the Dynabeads/mRNA hybrids, 500μl of washing buffer A was added to tube 
B to wash the Dynabeads/mRNA hybrids. Then the liquid was discarded after using a 
magnet to separate. This was the repeated 3 times and 500 μl of washing buffer B was 
used as per the steps with washing buffer A 2 times. Washing buffer A should be re-
moved as completely as possible before changing to washing buffer B. 
The compositions of all buffers/solutions used in mRNA isolation are listed below: 
Binding buffer: 20 Mm Tris-HCl pH 7.5, 1.0M LiCl, 2 mM EDTA 
Lysis/binding buffer: 100 mM Tris-Hcl pH 7.5, 500 mM LiCl, 10 mM EDTA, 1% 
LiDS, 5 mM Dithiothreitol(DTT). If any precipitation was observed, the solution was 
warmed to room temperature and shaken until all the components were fully resus-
pended. 
Washing buffer A: 10 mM Tris-HCl pH 7.5, 0.15 M LiCl, 1 mM EDTA, 0.1%LiDS 
Washing buffer B: 10 mM Tris-HCl pH 7.5, 0.15 M LiCl, 1 mM EDTA 
Elution buffer: 10 mM Tris-HCl pH 7.5 
Reconditioning solution: 0.1 M NaOH 
Storage buffer oligo (dT) 25: 250 mM Tris-HCL PH 7.5, 20 mM EDTA, 0.1% Tween-
20, 0.02% NaN3 
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For eluting mRNA from Dynabeads, tube B received 18 µl of Tris-HCl (10 mM) drop-
wise and the external tube wall was touched gently. Next, tube A was heated in a heat-
ing block at 80 ℃ for 2 min precisely, then it was placed on the magnetic rack imme-
diately. The supernatant containing mRNA was subsequently transferred to a PCR tube 
as quickly as possible.  
2.2.2 cDNA library construction 
A BD SMART™ RACE cDNA Amplification Kit (BD Bioscience Clontech, UK) was 
used in this part. A cDNA library could be constructed from isolated mRNAs by a 
reverse transcription polymerase chain reaction. In cDNA library construction, 
mRNAs acted as templates to synthesise first-strand cDNAs. For synthesising 3’-
RACE-Ready cDNA, 3’-CDS primer could combine with mRNA by hydrogen bonds 
and amplify a complementary chain. For synthesising 5’-RACE-Ready cDNA, apart 
from 5’-CDS primer, a modified oligo dT primer named BD SMART II™ A Oligonu-
cleotide (BD SMART II) was used to produce the first-strand cDNA by binding with 
the poly-A tail of mRNA. The primers used for cDNA library construction are listed 
in Table 2.1.  
 
Table 2.1 Sequences of primers for cDNA library construction 
 
All reagents were placed on ice to defrost and they were centrifuged briefly prior to 
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use. Then they were added to 5 PCR tubes labelled 3’-1, 3’-2, 3’-3, 5’-1, 5’-2 respec-
tively. Reagents were added to each PCR tube as shown in Table 2.2. After a brief 
centrifugation, PCR tubes were incubated at 70 ℃ for 2 min and cooled on ice for 2 
min. A master mix enough for 5 PCR tubes was prepared as well. After brief centrifu-
gation, 4 µl was transferred to each PCR tube. BD PowerScript™ Reverse Transcrip-
tase (BD RTase) was then taken out of the -20 ℃ freezer and centrifuged briefly. Next, 
1 µl of enzyme was added to each tube. Final components in each reaction tube are 
shown in Table 2.3 and Table 2.4. 
 
Table 2.2 Components for 5 PCR tubes 
 
 





Table 2.4 Components of each tube for 5’-RACE-Ready cDNA 
 
After all components in tubes were mixed well, these tubes were incubated at 42 ℃ 
for 1.5 h in a PCR machine (ThermoFisher Scientific, USA). After 1.5 h, 50 µl of PCR-
Grade water was added to each tube to dilute, then tubes were incubated at 72 ℃ for 
7 min to correct the possible error which might have been made at 42 ℃. Finally, PCR 
tubes which contained the cDNA library were stored at -20 ℃. 
2.2.3 RACE PCR  
The purpose of RACE PCR is to get massive double-stranded 3’-RACE fragments or 
5’-RACE fragments. In this section, only 3’-RACE PCR was performed and 3’-
RACE-Ready cDNA served as a template. The procedure was performed using the BD 
SMARTTM RACE cDNA AMPLIFICATION Kit(BD Bioscience Clontech, UK) as 
well. The sense primer is a degenerate primer pool and the antisense primer is nested 
universal primer (NUP). The sense primer (PD-S; 5’-GACCAAAGATGTCWTTCTT-
GAAGAAAT-3’) contained a highly-conserved domain of the 5’-untranslated region 
of previously-characterised homologous peptide cDNAs from Rana species (W=A or 
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T). The difference between the sample group and the negative control group was that 
the sample group has cDNA library. All reagents were taken out of the -20℃ freezer 
and placed on ice in advance to thaw thoroughly. The components in each reaction 
tube are shown in Table 2.5 and Table 2.6. 
 
Table 2.5 Components in each tube of sample group in RACE PCR 
 
 
Table 2.6 Components in each tube of negative control group in RACE PCR 
 
The RACE PCR programme was performed as shown in Table 2.7. After the whole 




Table 2.7 Programme for 3’-RACE PCR 
 
2.2.4 Gel electrophoresis for analysing RACE PCR products 
The purpose in this section is to separate different sized DNA fragments and detect 
whether the primer had annealed to cDNA template or not. Gel electrophoresis was 
used to separate and analyse DNA or other macromolecules by their different sizes and 
charges. The mechanism is that the negative charge DNAs moved to the anode and the 
small molecules migrate faster through the gel than the larger ones. Agarose is a com-
monly-used gel matrix in separating DNA. The DNA dyed by Ethidium Bromide(EB) 
could fluoresce under UV light. 
At first, an agarose gel (≥ 1% w/v) was made by mixing 0.45g agarose powder (Invi-
trogen, UK) with 35 ml of freshly prepared 1X Tris/Borate/EDTA (TBE) buffer (Invi-
trogen, UK) in a conical flask. The mixture was rotated and heated in a microwave 
oven until the agarose powder had dissolved in TBE buffer completely. After the flask 
was cooled, 2.5μl of 10 mg/ml EB (Sigma, UK) was added and was gently be rotated 
to mix. Then the mixture was poured into a dry gel electrophoresis tank which con-
tained two black gates, and a comb was put in the gel solution. All the bubbles in the 
mixture were removed and then the liquid was allowed to gel for about 30min. After 
the gel solidified, the comb was taken out and 1X TBE buffer was added to the reaction 
tank to just near the maximum level line. 
37 
 
Afterwards, the first well was loaded with 2.5µl of 100 bp DNA ladder (Invitrogen, 
UK) while other wells were loaded with a mixture of 0.5 µl loading dye (Invitrogen, 
UK) and 1.5µl of PACE PCR product. After all PCR products in different tubes were 
added to different wells in turn, the gel electrophoresis tank was covered and a contin-
uous current of 90 V was applied for about 30 min. And then, the gel was removed and 
placed under a Benchtop UV Transilluminator (UVP, UK) to detection. The size of 
PCR products could be estimated by comparing with DNA ladder. The brighter RACE 
PCR products which are larger than 300bp would be applied to the following experi-
ments. 
2.2.5 Purification of PACE PCR products. 
The 3’-RACE PCR products were purified using a Cycle Pure Kit (Omega Bio-Tek 
USA) to eliminate impurities such as buffer, polymerase and unreacted primers. Cha-
otropic solutions could interfere with non-covalent intramolecular interactions, in-
creasing the entropy of the system. Besides, salts possessed capabilities to shield 
charges, prevent stabilisation of salty bridges and destabilise hydrogen bonding. 
Therefore, double-stranded DNAs could be selectively adsorbed on the silica-based 
membrane of a cartridge in chaotropic salt solutions. Other compounds such as DNA 
polymerases and dNTPs could be removed with alcohol-containing wash buffer. Even-
tually, DNAs could be eluted with low-salt concentration solution or deionised water. 
The sample in Tube 1 and Tube 2, were mixed together in a 1.5mL tube (total 19μL). 
And then, 95μL CP Buffer was added in this tube (CP Buffer: Sample = 5:1(v/v)). After 
pipetting completely and evenly, all the solutions in this tube were transferred drop by 
drop onto the centre of a filter cartridge with a 1.5ml supporting tube. After that, the 
filter cartridge was centrifuged at 13.000 x g for 1 min in an Eppendorf Centrifuge 
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5424 (Eppendorf, Germany) to bind the DNA to the silica-based filter membranes and 
separate the impurities. Subsequently, the filtrate was discarded and the supporting 
tube was placed back in the cartridge and 700 μL of DNA Washing Buffer diluted in 
absolute ethanol was added into the cartridge and centrifuged at 13,000 x g for 1 min 
for DNA washing. And then, the filtrate was discarded after centrifugation and 500μL 
of DNA Washing buffer was added again. Then the cartridge with supporting tube was 
centrifuged at 13,000 x g for 1 min and the filtrate was discarded. Afterwards, the 
cartridge with supporting tube was centrifuged at 14,000 x g for 2 min to remove the 
remaining liquid completely as it could interfere with the downstream applications and 
then a new 1.5 ml DNase-free tube was used instead of the supporting tube before 
DNA collection. After that, 20 μL of PCR water was added directly into the centre of 
the cartridge for DNA elution and after a 2 min-incubation at room temperature, the 
cartridge was centrifuged at 14,000 x g for 1 min to collect all DNA products. The 
purified products in the 1.5 ml DNase-free tube were evaporated in a concentrator 
(Eppendorf, Germany) for 2h and the purified products was sealed with parafilm and 
stored at -20 ℃ in the freezer. 
2.2.6 Ligation of purified RACE PCR products into vector 
A pGEM®-T and pGEM®-T Easy Vector kit (Promega, USA) was employed for liga-
tion, transformation, blue and white colony screening and isolation of recombinant 
DNA reactions. Vectors were designed to have a 3’-T sticky end gap between Spe I to 
EcoR I in both strands. The Taq polymerase was able to add a single deoxyadenosine 
(A) at 3’-terminus in RACE PCR. This additional A annealed to the 3’Tsticky end in 
plasmid so that DNAs could bind with vectors at the insertion site. Each vector could 
only carry one DNA, isolating one from the other. 
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And then, 8 ul of PCR grade water were added into every tube containing DNA puri-
fication product to dissolve DNA and then the tubes were vortexed intermittently for 
1min and micro-centrifuged briefly to collect all contents at the bottom and then the 
tubes were placed on ice to cool for 30s. This step was repeated four times for DNA 
preparation. 2X Rapid Ligation Buffer was vortexed briefly and the pGEM®-T Easy 
Vector were micro-centrifuged briefly without pipetting to avoid damaging the fragile 
vectors. The T4 DNA Ligase was also micro-centrifuged briefly without pipetting as 
the enzyme was susceptible to inactivation under the changes of environment. The 
following prepared reagents were combined and mixed without pipetting in DNase-
free PCR tube. The components for ligation are shown in Table 2.8. 
 
Table 2.8 Components for ligation 
 
The 0.2 ml tube with ligation reaction product was incubated for 1h at room tempera-
ture and then incubated at 4 °C overnight (16-24h) in the thermal cycler. The vectors 
with a 3’ single terminal thymidine (T) in the insertion site were re-cyclised with a 
single guanosine (A)-ending DNA sequence derived from Taq DNA Polymerase 
through A-T base pairing. 
2.2.7 Transformation of recombinant DNA into competent JM109 cells 
In transformation, both recombinant and single plasmids were transferred into JM109 
cells and cultured on prepared Luria-Bertani (LB) agar Petri dishes and then they are 
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selected by ampicillin, IPTG and X-Gal using the pGEM®-T and pGEM®-T Easy 
Vector kit (Promega, USA). 
LB agar (Invitrogen, UK) was weighed and dissolved in 200 ml double deionised wa-
ter in a 400 ml glass bottle to obtain the LB agar solution (100 Unit/ml). The bottle 
was then autoclaved for sterilisation. And then 550ul of Ampicillin (Roche, USA) was 
added into the heated agar solution and mixed completely aiming to select the bacteria 
with the specific antibiotic resistance gene. Afterwards, 10 ml of heated agar solution 
was poured into each Petri dish. After the solidification of agar, all the plates were 
incubated upside down for 45 min at room temperature, and then the plates were ready 
for bacterial or cell culture. 
At first, 2.3ul of ligation products were transferred into a 1.5 ml DNase-free tube with-
out pipetting and the JM 109 cells (Promega, USA) were taken out of -80°C freezer 
and defrosted on ice box for 3.5 min until all were thawed and clarified. Then, 55ul of 
JM109 cells were added quickly to the 1.5 ml DNase-free tube containing ligation 
products. After that, the tube was flicked gently to mix the products and then keep on 
ice for 20 min. Subsequently, the tube was put in the heating block at exactly 42°C for 
47s to transfer ligation products into JM109 cells and then put the tube back to icebox 
immediately for 2 min. Subsequently, 950µl of SOC medium was added to the tube, 
and then the tube was incubated in orbital incubator at 37 ℃, 150 rpm for 2.5 h. After-
wards, 100 μl of Isopropyl β-D-thiogalactoside (IPTG) (Promega, USA) was added 
and spread into LB agar symmetrically and lightly as an inducer, which induced the 
expression of lacZ gene. Next, 20 μl of 5-Bromo-4-chloro-3-indolyl β-D-galactopyra-
noside (X-Gal) (Promega, USA) was added and spread over the surface of LB agar 
completely X-Gal can react with β-galactosidase which result in a colour change. Af-
terwards, all dishes were finally put upside down and incubated at 37 ℃ for 45 min. 
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Finally, 80ul, 90ul, 100ul and 110ul of transferred and spread over the surface of 
LB/Ampicillin/ ITPG/ X-Gal plates respectively in two replicates and all plates were 
incubated upside down at 37°C overnight (16-24 h) for bacterial culture and DNA am-
plification. 
2.2.8 Blue white screening for positive transformants 
The β-galactosidase is encoded by the lacZ gene region. IPTG, a lactose metabolite 
that triggers transcription of the lacZ operon, was used to induce the expression of β-
galactosidase. X-Gal, a colourless analogue of lactose, could produce an intense blue 
and insoluble product in the presence of β-galactosidase. In blue-white screening, 
IPTG and X-Gal acted as inducer and substrate respectively. When the inserted target 
DNA interrupted the lacZ region, β-galactosidase could not be expressed, causing 
JM109 cells to remain their original colour (white). On the contrast, vectors with entire 
lacZ operon could normally express β-galactosidase, causing the hydrolysis of X-Gal. 
In this section, blue-white screening was used to isolate recombinant vectors from all 
vectors. Three kinds of colonies were found on the LB/Ampicillin/ITPG/X-Gal plates 
from previous procedures including white colonies, blue colonies and white colonies 
with a blue dot. Pure white colonies and white colonies with a blue dot, in which the 
vectors were inside the competent cell and contained the recombinant DNA.  
Firstly, four dishes were prepared as per procedures in section 2.2.6 and these were 
labelled with squares (mostly 22 squares) on the bottom and marked with numbers and 
primer name. Subsequently, white colonies were numbered in accordance with the 
numbers of new dishes and then they were transferred to a new dish by using sterilised 
inoculating loop and they were gently dipped and drew in lines in new dishes. The new 
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dishes were put upside down and incubated at 37 ℃ overnight to let the bacteria con-
tinue growing. 
2.2.9 Isolation of recombinant DNA from JM109 cells 
After the overnight incubation, white colonies were selected and numbered at the bot-
tom of the plate and several 1.5ml tubes were labelled with the corresponding numbers. 
Next, 20ul PCR-Grade water was added to each tube and each square containing white 
colonies was scratched gently at a small angle by an autoclaved tip to collect all cells 
and the cells were transferred into the 1.5ml tube in accordance with the number. After 
that, the tubes were heated in a heating block at 100 ℃ for 5 min and then they were 
cooled on ice for 5 min to make the cell fragile. Then, each tube was vortexed for 30s 
to break the cell walls and release the vectors. Finally, the tubes containing recombi-
nant DNA were put into -20°C freezer. 
2.2.10 Cloning PCR 
In this section, the isolation of target DNA from the vector and target DNA amplifica-
tion relied on a cloning PDC reaction in which the M13 Forward Primer and M13 
Reverse Primer could bind to the 5’ and 3’ ends of inserted DNA, respectively. All the 
following components were placed on ice for a while to be defrosted and then centri-
fuged briefly prior to use. They were added to a tube as master mix and mixed com-




Table 2.9 The components of each tube in cloning PCR reaction 
 
At first, 47.5μl of master mix was added to each PCR tube respectively. Isolated DNA 
products were centrifuged at 14,000 x g for 5 min in an Eppendorf Centrifuge 5424 
(Eppendorf, Germany). Subsequently, 2.5 µl of supernatant containing recombinant 
DNA was added into each corresponding PCR tube and pipetted completely and 
evenly. All of the fourteen PCR tubes were put into fourteen 1.5 ml tubes respectively 
and they were centrifuged at 14,000 x g for 5 min to collect all contents at the bottom. 
After all components were prepared, the cloning PCR program was conducted as 
shown in Table 2.10. After this reaction, the 14 samples tubes were stored at -20°C in 
the freezer. 
 




2.2.11 Gel analysis of cloned PCR products 
The products of cloning PCR were mostly subjected to the gel electrophoresis as de-
scribed in section 2.2.3 except there was no loading-dye in the samples. The samples 
which showed a band at the proper position (usually the amounts of base pairs are two 
hundred more than before because of the M13F/M13R) were selected for following ex-
periments. 
2.2.12 Purification of cloned PCR products 
The selected PCR products were purified and washed out as described in section 2.2.4. 
However, instead of 30 μl of PCR water, 20 μl of PCR water was used in the DNA 
elution without evaporation at the end of purification. 
2.2.13 DNA sequencing reaction 
The aim of DNA sequencing reaction is to amplifying the purified cloned PCR prod-
ucts connected with M13F/M13R. However, instead of using dNTPs in PCR reactions, 
ddNTPs were used to stop extension of the new DNA chain. It is because ddNTPs lack 
an extra oxygen atom in deoxyribose. A Big Dye® Terminator v 3.1 Cycle Sequencing 
Kit (Applied Biosystems, USA) was used in the DNA sequencing reaction in which 
the sequence was detected by fluorescence during DNA extension and termination 
process. 
Firstly, four DNA samples were selected for the sequencing reaction. The following 
components were combined together by a brief centrifugation and gently pipetting, 
and an extra volume was calculated and added to ensure sufficient volume for the se-
quencing PCR reaction. Diluted M13F was made up of 10 µl of M13F primer and 52.5 




Table 2.11 Components in each sequencing reaction tube 
 
Next, 18.4 µl of the master mix was added into each four PCR tubes respectively, and 
2.5 μl of purified cloned PCR products was transferred into each PCR tubes and they 
were combined with master mix completely by gently pipetting. All reagents in PCR 
tubes were centrifuged briefly. 
All four PCR tubes were put into PCR machine and the run under a programme shown 
in Table 2.12. After the DNA sequencing reaction, the PCR products were kept at 4 ℃ 
in a freezer. 
 
Table 2.12 Programme for sequencing reaction 
 
2.2.14 Purification of extension products 
In the beginning, 10μl of PCR-Grade water was added to each 1.5 ml tube, and all the 
1.5 ml tube were labelled with the same numbers as PCR tubes. Then, 72 µl of 95% 
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ethanol (Sigma-Aldrich, USA) was added into the PCR containing sequencing reaction 
products and they were pipetted vigorously. Subsequently, all solution in the PCR 
tubes were transferred to the corresponding 1.5 ml tube with 10 μl PCR-Grade water. 
After that, all the tubes were vortexed for 30 s and incubated at room temperature for 
20 min and then they were centrifuged at 14,680 x g for 20min in an Eppendorf Cen-
trifuge 5424 (Eppendorf, Germany). After the centrifugation, the supernatant was dis-
carded as soon as possible to avoid redissolving the DNA in the supernatant again. 
Similarly, 260 μl of 70% ethanol were added to each 1.5 ml tube and they were vor-
texed for 30s. Then, they all the tubes were centrifuged at 14,680 x g for 10 min and 
the supernatants were discarded immediately. Next, all 1.5 ml tubes were heated in the 
heating block at 95°C for 1 min and then put on ice for 1 min with the lid of each tube 
open. This thermal cycle was repeated 3 times. At that, all the 1.5 ml tubes were sealed 
with sealing film and kept at room temperature. 
2.2.15 DNA sequencing 
At first, all four 1.5 tubes with purified extension DNA products were put into concen-
trator at 37°C for 1 h to dry the DNA and to drive the ethanol off. Next, 10.3 μl HiDi 
(highly deionised-formamide) was added to each sample. Then, all tubes were vor-
texed for 30 s and they were centrifuged briefly. Subsequently, the tubes were put into 
the heating block at 95°C for 4.5 min and then they were put on ice for 3 min. After 
that, all the tubes were centrifuged briefly and all of the well-prepared sample mixture 
was added into a 96-well sequencing plate without any bubbles, respectively. Finally, 




2.2.16 Bioinformatic analysis 
Chromas was used to scan the fluorogram. Then the Expert Protein Analysis System 
(ExpaSy) translate tool was applied to translate base sequences into protein sequence 
while the Basic Local Alignment Search Tool (BLAST) was used to search for proteins 
similar to the sequenced product. 
In this section, the spectrogram was examined manually and incorrect bases were mod-
ified in Chromas. After that, the sequence was translated into amino acids by the 
ExpaSy translate tool. Next, the translated peptide chain was compared with other 
chains in the database of the National Centre for Biotechnology Information (NCBI) 
by using BLAST. The similarity of the newly sequenced peptide to other known pep-
tides could thus be determined. 
 
2.3 Solid-Phase Peptide Synthesis 
The target peptide QUB-2552 was synthesised efficiently by solid phase Fluorenyl-
methoxycarbonyl (Fmoc) chemistry in a PS4 synthesiser (Protein Technologies, USA). 
The primary structure of the peptide was as follows: 
VLPFVAGVAAEMMQHVYCAASKKC. The first amino acid was linked with a pol-
ymeric resin at the C-terminus. Other amino acids were protected by Fmoc (9-fluo-
renylmethoxycarbonyl) groups and they were added sequentially to this through a se-
ries of coupling and washing steps until the sequence was completed. 
 
2.3.1 Synthesis using the Tribute synthesiser 
To synthesis 0.15mmol peptide, each amino acid should be 4 times than 0.15mmol. 
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Thus 0.6mmol of every amino acid in the sequence was required. Also, 0.6mmol of 
HBTU [2- (1H- benzotriazol -1- yl) -1, 1, 3, 3- tetramethyluronium hexaﬂuorophos-
phate] was required and they were mixed with 0.6mmol of every amino acid in vials 
to catalyse each coupling. The required 0.15mmol resin [weight (g) = 0.15mmol / load-
ing capacity (0.57mmol/g)] was added into the reaction vessel just before synthesis. 
All amino acid vials were put in correct place corresponding to the order of amino acid 
from C-terminal to N-terminal in the peptide. The inline solvent filters and the source 
of nitrogen were checked before the operation. DMF (N, N-Dimethylformamaide), 
NMM (4-methylmorpholine) and Piperidine were required for synthesis. 
After all reagents have been prepared, the peptide synthesiser was run with the pro-
gramme as follows: 
Step Reagent Action Time Mix type Drain 
Re-
peat 







10s N2, Vortex Yes 3 







10s N2, Vortex Yes 1 
5 Amino Acid Coupling 10s / / 1 
6 / Mix / N2, Vortex Yes / 
 
Table 2.13 The major programme of the peptide synthesiser. 
When the synthesis was complete, the reaction vessel was sealed by pierced parafilm and dried in a 




2.3.2 Cleavage Reaction 
The resin linked with synthesised peptide was weighed and transferred into a 50 ml 
round-bottomed flask with a magnetic rotor. The cleavage cocktail (25ml/g resin, 94% 
TFA + 2% EDT + 2%TIS + 2% H2O) was prepared and added to the flask to deprotect 
the protecting groups of side chains. The cleavage reaction was performed by stirring 
at room temperature for 2.5h. After that, the cleavage mixture was filtered into another 
new flask by using the Buchner funnel. Then, the new flask was put to the rotary evap-
orator (VWR, Pennsylvania, USA) to remove TFA. During, the process, the water bath 
was kept at less than 40℃. Finally, 45ml Et2O was added to the flask then transferred 
to a 50ml universal tube. The product was labelled and placed into a -20℃ freezer 
overnight to get the peptide precipitation. 
2.3.3 Washing and lyophilisation 
The above universal tube was taken out of the freezer and they were vortexed com-
pletely to make the peptide dissolve in Et2O. Subsequently, the universal tube was 
centrifuged at 7830 x g for 15 min to collect the precipitated peptide at the bottom. 
And then, the supernatant in the universal tube was discard and 5ml of Et2O was added 
into it. This washing step was repeated 3 times, and the only difference is that the 
vortex time in second time and the third time is 10 min and 5 min, respectively. Next, 
the universal tube with the covering foil pierced by a needle was put in a vacuum 
desiccator to evaporate the Et2O. After that, 30 ml Solution B (80%Acetonitrile, 20% 
H2O) was used to dissolve completely and 60 μl of 0.2% H2O2 was added to oxygenize 
Cys. The tube was then snap frozen in liquid nitrogen and then transferred into an 
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Llpha 1-2 freeze-dryer (SciQuip, UK) for around 72 h.  
2.4 Identification and Purification of peptides 
To identify and assess the purity of the synthesised peptide QUB-2552, the synthesised 
peptide was subject to MALDI-TOF mass spectrometry and RP-HPLC. 
 
2.4.1 Peptide analysis by Matrix-assisted laser desorption ionisation time-of-flight 
mass spectrometry 
MALDI-TOF mass spectrometry was used for peptide identification by mass analysis 
using a linear time-of-flight mass spectrometer (Voyager DE, PerSeptive Biosystems, 
Framingham, MA, USA) in positive detection mode. Internal mass calibration was 
verified using the standard peptides corresponding with standard molecular masses to 
ensure high accuracy of ±0.1%. 1 μl of HPLC fraction was loaded and spotted onto 
the MALDI ground-steel target plate, and 1μl excess matrix solution (10 mg/ml) which 
containedα-cyano-4-hydroxycinnamic acid (CHCA) diluted in acetonitrile/water/TFA 
(50/49.7/0.3, v/v/v) was also loaded and spotted after air-drying of the fraction. The 
configuration of the system was set at 120ns, 18.8kV grid voltage, 10V guide wire and 
delayed extraction and the linear model was chosen to record the mass spectra. The 
peptide was identified by mass by mass measurement according to its mass-to-charge 
ratios. Finally, the pure peptide was obtained and subjected to lyophilisation and bio-
logical activity assay. 
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2.4.2 Reversed-phase high performance liquid chromatography (HPLC) 
Firstly, 1 mg of crude lyophilised peptide was weighed and diluted in a 1.5 ml universal 
tube with 1 ml Buffer A (TFA/water, 0.5/99.95). Then, the tube was vortexed and cen-
trifuged at maximum speed for 15 min. The clear supernatant was transferred into an-
other 1.5 ml tube. An analytical reverse phase HPLC Jupiter C5 column 
(250nm*4.6mm, Phenomenex, UK) was washed with Buffer B for 30 min and equili-
brated in Buffer A for 30 min before using. Subsequently, 1 ml of clear supernatant 
was pumped onto the Jupiter C5 column on a Cecil Adept CE4200 HPLC system 
(Cecil, Cambridge, UK) for peptide elution and purification with 214nm wavelength 
detection. The peptide was eluted from the column with a linear gradient from 100% 
Buffer A mixed 0% Buffer to 100% Buffer B over 80 min at a flow rate of 1ml/min. 
The fractions were collected at every peak in polypropylene tube (Sarstedt, Germany) 
using an Amersham Biosciences Frac-920 fraction collector and utilised for identifi-
cation. 
 
2.5 Antimicrobial activity assays 
This experiment was conducted to test the minimum inhibitory concentrations (MICs) 
and minimum bactericidal concentrations (MBCs) of the peptide towards three differ-
ent microorganisms, Staphylococcus aureus (S. aureus), Escherichia coli (E. coli) and 
Candida albicans (C. albicans). The MIC is defined as the minimal concentration that 
an antimicrobial can inhibit the growth of a microorganism. The MBC is defined as 




2.5.1 Inoculation of microorganisms 
A bead of each microbial culture was taken from frozen storage and placed into sepa-
rately marked flasks containing 100 ml MHB (Mueller Hinton Broth) medium. The 
flask was incubated in an orbital incubator at 37 ℃, 150-200 rpm for 16-20 h. Bottles 
of 20 ml MHB were incubated at 37 ℃ for 2 h to pre-warm. 
2.5.2 Dissolving of QUB-2552 
QUB-2552 was weighed and dissolved in dimethyl sulphoxide (DMSO) (Fisher 
Chemical, UK) to get a concentration of 512 x 102 µM. The solution was then mixed 
and centrifuged prior to use. The peptide solution was then diluted and the peptide was 
added to 96-well plate at a series of concentrations: 256, 128, 64, 32, 16, 8, 4, 2, 1 µM. 
2.5.3 Subculture of microorganisms 
Firstly, 500 μl of microbial culture was transferred into a pre-warm McCartney bottle 
with 20 ml MHB medium. Next, the McCartney bottle was incubated in the orbital 
incubator (Stuart, UK) at 37°C until the microbes have grown to the required optical 
density (OD) (Table 2.14). The optical density (OD) value of the subcultured bacteria 
was measured using a UV spectrometer at 550 nm wavelength.  
2.5.4 Dilution of subcultured microbial suspensions 
When the microbes have grown the required optical density (OD), in order to get the 
final concentration of 5*105 cfu/ml of microbe, 100 μl of subculture supernatant of S. 
aureus or E. coli was transferred into a Petri dish with 19.9 ml pre-warm MHB medium 
and they are mixed thoroughly. As for C. albicans, 2 ml of subculture suspension was 




Table 2.14 The appropriate OD values for the three microorganisms used in this assay 
 
2.5.5 Determining minimum inhibitory concentrations (MICs) of QUB-2552 
The 96-well plate used in the MIC assay was divided into four groups: negative control 
group, growth control group, vehicle control group and sample group. The components 
in each group are shown in Table 2.15. The plate was incubated at 37 ℃, 150-200 rpm 
for 5-10 min and incubated in an incubator at 37 ℃ for 16-20 h. After incubation, the 
96-well plate was detected in a Synergy HT plate reader (BioTek, USA) at a wave-
length of 550 nm.  
 
Table 2.15 Components of each group in 96-well plate in MIC assay. Negative control was used to 
eliminate the influence of solvent. Growth control was used to detect the normal growth of microor-




2.5.6 Viable cell counts 
Firstly, 100 μl of diluted microbial suspensions was transferred into the microbe with 
900μl of phosphate-buffered saline (PBS) and they were mixed completely. Then, 10-
fold dilutions of this were prepared from 10-1 M to 10-6 M. After that, 20 μl of diluted 
suspensions were dropped onto the pre-prepared Mueller Hinton Agar (MHA) plate 
with three replications for each concentration and all the liquid drops were air-dried 
near the Bunsen burner. Then the MHA plate was incubated in the incubator (Genlab 
Limited, UK) at 37°C overnight (16-20 h). A countable grid was chosen in the MHA 
Petri dish after culturing to count numbers of colonies. Finally, the exact concentra-
tions of bacteria were calculated using the following formula: C=N/3*50*10n, where 
N represented the total quantity of the organisms at each concentration while n was 
radio of dilution. The result shows that the viable counts are the same as the required 
optical density. 
2.5.7 Determining minimum bactericidal concentrations (MBCs) of QUB-2552 
After the 96-well plate was detected in MIC assay, 10μL of the solution at each con-
centration of the peptide was transferred from the 96-well plate into prepared petri 
dishes containing MHA medium. Each concentration had three replications. And then, 
the plates were incubated into an incubator for 24h. Finally, the plates were taken from 
incubator and to determine whether the bacteria can grow at each concentration of the 
peptide. 
2.6 Anticancer cell activity assays of QUB-2552 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), a tetrazole, can 
be reduced to insoluble purple formazan in living cells in the presence of mitochondrial 
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dehydrogenase. DMSO can dissolve the purple precipitate, and the absorbance of the 
solution can be assessed at the wavelength of 570 nm. Therefore, the viability of cancer 
cells challenged by peptide solutions can be evaluated by comparing the absorbance 
with unchallenged cells. The cancer cell lines used in this section were shown in Table 
2.16. 
 
Table 2.16 Cell lines used in the anticancer cell assays. Both H157 and PC-3 were cultured in RPMI 
1640 medium (Life Technologies, UK) while MCF-7 and U251MG were cultured in DMEM medium 
(Life Technologies, UK). 
 
2.6.1 Cell culture 
2.6.1.1 Cell resuscitation 
The cell lines used for this bioassay included PC-3 (human prostate carcinoma, GIV), 
H157 (non-small cell lung cancer), MCF-7 (Michigan Cancer Foundation-7) and 
U251MG (Human neuronal glioblastoma). The cell lines U251MG and MCF-7 were 
cultured by full-growth-DMEM medium containing 10% foetal bovine serum (FBS) 
(Sigma-Aldrich, USA) and 1% penicillin-streptomycin (P-S) (Sigma-Aldrich, USA). 
The cell lines PC-3 and H157 were cultured by full-growth-1640 medium containing 
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10% foetal bovine serum (FBS) (Sigma-Aldrich, USA) and 1% penicillin-streptomy-
cin (P-S) (Sigma-Aldrich, USA).To begin with, 15 ml of medium was transferred to a 
medium-sized culture flask (Sigma-Aldrich, USA). The frozen cells were removed 
from an 80°C freezer and thawed in a pre-warmed 37°C water bath. Then, 1 ml cells 
were transferred to the flask and the flask was shaken gently to mix medium and cells 
thoroughly. Finally, the culture flask was incubated at 37°C atmosphere containing 
with 5% CO2 after cell examination by an inverted microscope. 
 
2.6.1.2 Changing media 
Firstly, spent medium was discarded from flask after the cell examination and then 10 
ml pre-warmed PBS solution was added into the culture flask followed by swaying 
gently to wash cells. Next, all liquid in the flask was discarded and 15ml of new pre-
warmed full-growth medium was added into the flask and then the flask was shaken 
gently. Finally, the flask was cultured in an incubator at 37 ℃ under 5% CO2. When 
the inner bottom surface of the flask was confluent with 90% cells, the passage was 
necessary to ensure enough growing environment and nutrition for cells. 
 
2.6.1.3 Cell passage 
To begin with, all spent medium was discarded and 10 ml of pre-warmed PBS was 
added into the flask followed by swaying gently to wash cells. After the PBS in the 
flask was discarded, 1000 µl of 0.5% trypsin solution (Life Technology, USA) was 
added to a flask to digest cells. Then, the flask was shaken gently and put into an in-
cubator at 37 ℃ with 5% CO2 for about 2 min. When the cells became detached, 10 ml 
of new pre-warmed full-growth medium was added into the flask with the aspiration 
to stop trypsin digestion. Subsequently, all the cell suspension was transferred into a 
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15 ml universal tube and the tube was centrifuged at 380 rcf for 5 min in an Eppendorf 
Centrifuge 5430R (Eppendorf, Germany). Meanwhile, the culture flask was washed 
with 10 ml of PBS and then 15 ml of new medium was added into it. After centrifuga-
tion, the supernatants in the tube was discarded and then 5 ml of pre-warmed full-
growth medium was added into the 15 ml universal tube to mix with cells thoroughly. 
Finally, 2 ml of cell suspension was transferred into the culture flask containing full-
growth medium and the flask was then incubated at 37°C in a humidified environment 
containing 5% CO2 after cell examination. 
2.6.2 MTT cell viability assay 
2.6.2.1 Cell seeding  
These procedures were the same as those in cell passage before the centrifugation step. 
After 5 ml of new full-growth medium was added and mixed completely in the tube in 
passaging, 50 µl of cell suspension and 50 µl of 0.5% trypan blue were mixed in a 0.2 
ml universal tube. Then 50 µl of the mixture was added to two chambers of a haemo-
cytometer. The haemocytometer was put under an inverted microscope to count cells 
and cells in 8 grids at three corners were counted.  After that, cell suspensions were 
diluted by full-growth medium to ensure that the cell number in 100 µl of the suspen-
sion was 5000. Subsequently, 100 µl of diluted cell suspension was added to every 
well by a multichannel pipette. The plate was cultured for 24 h before starvation. Fi-
nally, 1 ml of the suspension was transferred into the cleaned flask to continue cultur-
ing while other cells were disposed of. 
The dilution rate was calculated as follows: 




2.6.2.2 Starvation  
The former full-growth medium in every well was discarded by using a pipette and 
then 100 µl of the new pre-warmed FBS-free medium was added to each well by a 
multichannel pipette. The plate was then incubated at 37°C under 5% CO2 in the hu-
midified atmosphere for 6-12h to starve the cells which can eliminate the impact of 
FBS. 
 
2.6.2.3 Peptide preparation and loading 
Firstly, 1 mg of peptide QUB-2552 was weighed and dissolved in DMSO to get a stock 
solution in the concentration of 10-2 M. Then, the stock was diluted in the final con-
centration of 10-5 M by using FBS-free medium. Meanwhile 1 % DMSO was prepared 
by using DMSO and FBS-free medium. After peptide and 1% DMSO were prepared 
and medium in 96-well plate was removed, 100 µl of peptide which was at the con-
centration of 10-5 M were loaded to the well of 96-well plate in 3 replicates. Then, 
100µl of FBS-free medium was added as a positive control and 100 µl of 1% DMSO 
solution was also added as a vehicle control to reflect the impact of 1% DMSO on the 
cell growth. Finally, the 96-well plate was incubated at 37°C in humidified surround-
ing with 5% CO2 treated for 24 h.  
2.6.2.4 MTT cell viability assay 
The MTT solution (5 mg/ml, ThermoFisher Scientific, USA) was taken from the 4 ℃ 
fridge. And 10 µl of MTT was added in each well in 96-well plate. All the former step 
was performed in a dim place. And then, the plated was incubated for 4 h in an incu-
bator. After that, all the liquid in 96-well plate was discarded and 100 µl of DMSO was 
added in each well in 96-well plate. Subsequently, the plate was shaken at maximum 
speed (250 rpm) for 10 min. Finally, the absorbance of solutions was determined at 
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570 nm. The cell viability was calculated as follows. 
Viability% = A / A0 x 100%  
The A represents the average absorbance of sample groups in the same concentration. 
A0 represents for the average absorbance of vehicle control. 
 
2.7 Haemolysis assay 
2.7.1 Peptide and control preparation  
Firstly, 3.14 mg of peptide were weighed and dissolved in PBS solution to get the stock 
with the concentration of 1024 μM. Then, the stock was diluted by PBS solution to get 
a range of gradient concentrations including 1024, 512, 256, 128, 64, 32, 16, 8, 4, 2 
μM and the stock of each concentration is 600 μl. Meanwhile, 2 ml of Triton X-100 
(Sigma Aldrich, St. Louis, MO, USA) was diluted in 18 ml of PBS solution as a posi-
tive control in which 1% (v/v) non-ionic detergent Triton X-100 can produce a 70% 
haemolytic effect. 
2.7.2 Horse blood preparation 
Firstly, 2 ml of fresh horse blood (TCS Biosciences Ltd, Buckingham, UK) were added 
into a 50 ml universal tube and centrifuged at 930 x g for 5 min to separate the serum 
from erythrocytes. Then, the supernatant was discarded and 30 ml of PBS solution was 
added. The washing step were repeated until the supernatant was clear. Subsequently, 
the supernatant was discarded and 50 ml of sterile PBS solution was added into the 50 




2.7.3 Haemolysis assay 
Firstly, 100 μl of prepared peptide dilutions at each concentration, 1% Triton X-100 
dilution and PBS solution was added into each 1.5 ml universal tubes in 5 replicates. 
Afterwards, 100 μl of erythrocyte suspension was added slowly into each 1.5 tube and 
incubated in the incubator Genlab Limited, UK) at 37°C for 2 h. After that, all 1.5 ml 
tubes were centrifuged at 930 x g for 5 min and 100 μl of supernatant was transferred 
from each tube into wells of a 96-well plate. Finally, the absorbance of the supernatant 
was measured using a Synergy HT plate reader (BioTek, USA) at 550 nm wavelength. 
The percentage of haemolysis was calculated using the following formula and a graph 
was drawn. 














































































3.1 “Shotgun” cloning of QUB-2552 precursor-encoding cDNAs 
The obtained precursor-encoding cDNA sequence was translated into amino acid se-
quence by using Expert Protein Analysis System (ExPASY) (Available at: 
https://www.expasy.org, accessed on: 25th January, 2018) 
As shown in Figure 3.1, the open-reading frame was constituted by 68 amino acids. 
The first amino acid was methionine (M) which was encoded by a start codon (ATG). 
The following region was the putative signal peptide containing 22 amino acid resi-
dues, followed by a spacer domain which was rich in acidic amino acid residues. After 
a specific cleavage site or release site –Lys-Arg- (-KR-), the following 24 amino acids 
are the sequence of the mature peptide. 
As shown in Figure 3.2, a sequence alignment performed by CLUSTAL OMEGA 
showed that the open-reading frame of the QUB-2552 sequence exhibited high se-
quence identity with the following five peptides: lividin-1a (Odorrana livida); Odor-
ranain-P1b and Odorranain-P-RA2 (Odorrana graham); Brevinin-1-0mar5 (Odor-
rana margaretae); nigrocin-6EV1 (Odorrana exiliversabilis). According to the 
BLAST analysis, the primary structure of the putative mature peptide 
(VLPFVAGVAAEMMQHVYCAASKKC) was 96% identical to lividin-1a 
(ILPFVAGVAAEMMQHVYCAASKKC) which was previously identified form 




Figure 3.1 Nucleotide sequence and corresponding open-reading frame of the QUB-2552 peptide pre-
cursor encoding cDNA cloned from an Odorrana livida skin secretion-derived cDNA library. Putative 
signal peptide is double-underlined, deduced mature peptide is single-underlined and the stop codon is 
indicated by an asterisk. 
 
 
Figure 3.2 An alignment of the mature peptide sequences encoding QUB-2552 and five other peptides 
from the same or related frog genera. Identical amino acid is indicated by asterisks. 
3.2 Synthesis of QUB-2552 
After the synthetic product was identified by MALDI-TOF MS, the result showed that 
64 
 
the peptide QUB2552 was successfully synthesised by using the PS4 automated syn-
thesizer.  
 
3.3 Identification and purification of QUB-2552 
Firstly, MALDI-TOF MS analysis was firstly used to determine whether the QUB-
2552 peptide has been successfully synthesised. After that, it was performed to analyse 
the product of RP-HPLC chromatogram to determine which eluted fraction contained 
the purified portion of QUB-2552 peptide. As shown in Figure 3.3, the mass-to-charge 
ratio value of the highest peak was 2590.08, which was larger than the mass-to-charge 
ratio value of QUB-2552 peptide. It is assumed that it was because that a chloridion in 
the matrix solution was bond to QUB-2552 peptide when they were mixed together, 
and the calibration of MALDI-TOF MS instrument needs to be corrected to make it 
more accurate. Thus, the mass-to-charge ratio value of the highest peak was 2590.08 
rather than 2552. Together, as shown in Figure 3.3, the QUB-2552 peptide was suc-


















































The synthetic peptide was subjected to RP-HPLC analysis. 
 
 
Figure 3.4 RP-HPLC chromatogram of the synthetic QUB-2552 peptide. The arrow indicates the re-
tention time of the fraction that containing QUB-2552. 
 
The fractions collected from by RP-HPLC were subjected to MALDI-TOF MS to iden-
tify which fraction contains the purified portion of QUB-2552 peptide. As shown in 
Figure 3.4, the arrow indicated the retention time of the fraction, which contains puri-
fied the synthetic QUB-2552. After that, the purified peptide product was freeze-dried 
and stored in a freezer for further use. 
 
3.4 QUB-2552 antimicrobial effect against S. aureus and C. albicans 
Through the antimicrobial evaluation, QUB-2552 peptide a showed moderate antimi-
crobial effect against S. aureus and C. albicans, but it didn’t exhibit antimicrobial ef-
fect against E. coli. 




𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟𝑦 𝑅𝑎𝑡𝑒 = (1 −
𝐴𝑠 − 𝐴𝑏
𝐴𝑐 − 𝐴𝑏 
) ∗ 100% 
(As = absorbance of sample solution; Ab = absorbance of blank control and Ac = ab-
sorbance of vehicle control.) 
 
The results of antimicrobial effect of the QUB-2552 peptide against S. aureus was 
shown in Figure 3.5, the synthetic QUB-2552 peptide exhibited a moderate inhibitory 
activity against the Gram-positive microorganism, S. aureus. The MIC value was 256 
μM. And the QUB-2552 peptide did not exhibit MBC value in S. aureus at the con-
centrations ranging from 1 μM to 512 μM. 
 
 
Figure 3.5 Antimicrobial activity of QUB-2552 against S. aureus. The MIC value is 256 μM where 
the inhibitory percentage is 70%. The vehicle is 1% DMSO. 
 
The results of the antimicrobial effect of the QUB-2552 peptide against E. coli was 
shown in Figure 3.6, the synthetic QUB-2552 peptide did not exert any inhibitory 
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activity against the Gram-negative microorganism, E. coli, at the concentration up to 
512μM. Thus, the MBC experiment with E. coli was not performed. 
 
Figure 3.6 Antimicrobial activity of QUB-2552 against E. coli. The vehicle is 1% DMSO. 
 
 
The synthetic peptide QUB-2552 had moderate effectiveness against the yeast, C. al-
bicans, which was shown in Figure 3.7. The MIC value was 256 μM. While the MBC 






Figure 3.7 Antimicrobial activity of QUB-2552 against C. albicans. The MIC value is 256 μM 
where the inhibitory percentage is 0.7%. The vehicle is 1% DMSO. 
 
3.5 QUB-2552 anti-cancer activity 
The anti-cancer activity of the synthetic QUB-2552 peptide was examined on four 
cancer cell lines at the concentration of 10-5 M. As shown in Figure 3.8, the synthetic 
peptide does not has inhibitory effect against MCF-7 and PC-3 at the concentration of 
10-5M, but it has weak inhibitory effect against U251MG and H-157 at the concentra-




Figure 3.8 Anti-cancer activity of QUB-2552 against four cell lines at the concentration of 10-5 
M. The negative sample is culture medium. Asterisks indicate ** p≤0.01, *p≤0.05. NS indicates 
no significant difference. 
 
3.5 QUB-2552 haemolytic activity 





(As = absorbance of sample solution; An= absorbance of negative control; Ap = ab-
sorbance of positive control.) 
As shown in Figure 3.9, the synthetic QUB-2552 peptide did not exhibit haemolytic 
































































Amphibians inhabit both in land and water, which forces them to survive and adapt to 
complicated environment and hostile predators. Thus, it is not surprising that the skin 
secretion of amphibians contains a wide range of chemical compounds, of which bio-
logical peptides are predominant compounds, and it is generally presumed that AMPs 
play a critical role in the immune system of amphibians (Hancock et al., 2012). In 
recent years, antibiotic resistance has become a challenge, and it is necessary to find 
new kinds of antibiotics. As described in Chapter 1, the major mechanism of AMPs 
action is to destroy bacterial membrane integrity, which is less likely to cause antimi-
crobial resistance. Thus, AMPs have been studied by many researchers and AMPs are 
proposed to be promising antimicrobial agents (Seo et al., 2012). 
 
This research has led to the discovery of a cDNA encoding precursor novel peptide 
QUB-2552 from the skin secretion of Chinese Large Odorous frog, Rana (Odorrana) 
livida. Generally, all the AMPs discovered from the genus Rana has hydrophobic sec-
ondary structure and can form an amphipathic α-helix in a membrane-mimetic solvent. 
QUB-2552 also has these structure characteristics. Its primary structure is mostly con-
sisted by non-polar residues (Ala 20.8%, Val 16.7%, Met 8.3%, Gly 4.2%, Leu 4.2%, 
Phe 4.2%, Tyr 4.2%). The polar residues (Pro 4.2%, Glu 4.2%, Gln 4.2%, His 4.2%, 
Ser 4.2%, Cys 8.3%, Lys 8.3%) interspersed in hydrophobic groups to provide the 
potential of forming amphipathic α-helix. All these characteristics play an important 
role in its biological activities. QUB-2552 also has the C-terminal intra-disulphide 
bridge known as a “Rana box”, and it is proposed to increase helix stability (Wang, 
2012).  
 
The predicted secondary structure of QUB-2552 are described as follows. As shown 
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in the Figure 4.1 and Figure 4.2, QUB-2552 also has a high content of α-helix. A study 
of the α-helical wheel plot of QUB-2552 (Figure 4.3), shows that this peptide has an 
amphipathic distribution of hydrophobic and hydrophilic amino acids and the net 
charge is 1+. These features may contribute to its antimicrobial effects, which fits the 
hypothesis of the mechanism of AMPs action described in Chapter 1 (Dathe and 
Wieprecht, 1999) 
 
Figure 4.1 Predicted secondary structure of QUB-2552 peptide 
 




Figure 4.3 The α-helical wheel plot of peptide QUB-2552 
From the results shown in Chapter 3, it is presumed that this peptide has a moderate 
effect in inhibiting Gram-positive bacteria and fungi, and it does not show inhibitory 
effect against Gram-negative bacteria. Besides, it does not has inhibitory effect against 
MCF-7 and PC-3, but it has weak inhibitory effect against U251MG and H-157. Fur-
thermore, it does not possess the haemolytic effect against horse blood cell. 
 
In antimicrobial activity evaluation, the MICs of QUB-2552 against S. aureus (Gram-
positive bacteria) and C. albicans (Fungus) are 512μM and 256μM, respectively. And 
the QUB-2552 didn’t show inhibitory effect against E.coli (Gram-negative bacteria). 
In haemolysis assay, the cytotoxicity of QUB-2552 towards eukaryotic cells was eval-
uated and the peptide did not show haemolysis activity against horse red blood cell. 
The different effect against these three microorganisms and horse red blood cell may 
be explained by their different cell membrane structures. 
 
To penetrate into the cell membrane of S. aureus (Gram-positive bacteria), peptides 
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need to insert into the multiple cross-linked peptidoglycan layer. The percentage of 
each components of the cell membrane was 57% lysylphosphatidylglycerol, 36% PG 
and 7% cardiolipin (CL) (Haest et al., 1972). The combination of these compositions 
contribute to the negative charge of the cell membrane, which may help the positively 
charged groups of QUB-2552 peptide bind to the negatively charge cell membrane. 
Meanwhile, the peptidoglycan as the main composition of the cell wall of S. aureus 
could interact with QUB-2552 peptides and might facilitate its penetration (Shai, 2002). 
The composition of the outer membrane of E. coli (Gram-negative bacteria) is 91.4% 
phosphatidylethanolamine (PE), 3.0% phosphatidylglycerol (PG) and 5.6% diphos-
phatidylglycerol (DPG). Besides, the composition of the cytoplasmic membrane is 
81.7% PE, 6.5% PG and 11.8% DPG (Lugtenberg and Peters, 1976). To go through 
the cell membrane of E.coli, peptides need to penetrate both the inner and outer mem-
branes. The outer membrane is believed to be the main reason why some AMPs do not 
possess anti-Gram-negative activity (Papo and Shai, 2005). 
 
The main phospholipid components of C.albicans (Fungus) are the phosphatidyleth-
anolamine (PE), phosphatidylcholine (PC) and sphingomyelin (SM). These compo-
nents could contribute to the net charge of the cell wall of C.albicans (Mago and 
Khuller, 1990). However, the cell membrane of erythrocytes is mainly composed of 
zwitterionic phosphatidylcholine, cholesterol and sphingomyelin. Thus, erythrocytes 
has zwitterionic cell membrane (Schmidtchen et al., 2014). In sum, the cell membrane 
of C. albicans is negatively charged and lack cholesterol, while the cell membrane of 
erythrocytes is zwitterionic and has cholesterol. There features may contributes to the 




The experiments carried out in this study only involved a narrow range of biological 
identifications. Thus, more investigations need to be carried out to gain clearer picture 
of bioactivity spectra and to further our knowledge of this novel bioactive peptide. In 
the future, it is necessary to make some modification of this peptide to improve the 
antimicrobial property but keep the low haemolytic activity. The optimization of the 
hydrophobicity and cationicity could be employed. For example, substituting acidic 
and neutral amino acid residues with cationic amino acids such as Lys could improve 
the cationicity of the peptide, and it is possible to promote the attachment ability of the 
peptide to bacteria cell membrane. Besides, substituting acidic and neutral amino acid 
residues with hydrophobic amino acids such as Leu on nonpolar face of the α-helix 
can improve the hydrophobicity of the peptide, which may enhance the penetration 
ability into the target cells. Furthermore, there are other methods which could be used. 
For example, introducing D-amino acids into the sequence of QUB-2552, encapsulat-
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